Angiotensin II Antagonists
Summary: Benefits of eprosartan for patients with high blood pressure
Eprosartan helps achieve success in all grades of hypertension including severe hypertension, in a wide range of patients.
-
The systolic component of blood pressure is a better predictor of cerebrovascular and cardiovascular risk than the diastolic component. Most hypertensive people over the age of 50 years have predominantly systolic hypertension. Eprosartan gives a statistically significantly greater reduction of systolic blood pressure than enalapril
-
Recurrent stroke is a major cause of death and disability. The MOSES study has shown that eprosartan reduces secondary stroke in hypertensive patients, and is statistically significantly more effective than a calcium channel blocker.
-
Cough is a frequent problem with ACE inhibitors. Eprosartan causes a lower incidence of dry, persistent cough than enalapril (comparable incidence to placebo).
-
Eprosartan is effective in Afro-Caribbeans, who may be less responsive to some other treatments such as ACE inhibitors.
-
Eprosartan gives effective 24-hour control of hypertension from a single 600mg once-daily starting and maintenance dose for most patients. It is also associated with a low incidence of adverse events. This makes it suitable for patients who are not fully concordant with their current treatment, either because of side effects or because their current treatment is not effective.
-
The dose of eprosartan can be increased with no significant increase in adverse effects. It can also be combined with various other antihypertensive agents such as HCTZ.
-
For patients taking concomitant medications, eprosartan will not interfere with their metabolism by cytochrome P450 enzymes.